Critical review of non-statin treatments for dyslipoproteinemia

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 3, 2014, Pages 359-371

  Pang, Jing ^a   Chan, Dick C ^a   Watts, Gerald F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

dyslipidemia; familial combined hyperlipidemia; familial hypercholesterolemia; hypertriglyceridemia; lipoprotein(a); metabolic syndrome; new therapy; statin intolerance; treatment; Type 2 diabetes

Indexed keywords

ANGIOPOIETIN LIKE PROTEIN INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; MIPOMERSEN; NICOTINIC ACID; NUTRACEUTICAL; OBETICHOLIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

APHERESIS; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FOOD AND DRUG ADMINISTRATION; GENE REPLACEMENT THERAPY; HEART PROTECTION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LOW FAT DIET; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; GENETIC THERAPY; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 84896768836     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.888312     Document Type: Review

References (206)

1. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(Suppl 1):S11-63
2. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34(39):3035-87
3. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol < 50 mg/dl with rosuvastatinthe JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57(16): 1666-75
4. Waters DD, Brotons C, Chiang C-W, et al. Lipid treatment assessment project 2 a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol Goals. Circulation 2009;120(1):28-34
5. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32(14):1769-818
6. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33(13):1635-701
7. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013. [Epub ahead of print]
8. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78(6):393-403
9. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: canadian Working Group consensus update. Can J Cardiol 2011;27(5):635-62
10. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172(2):144-52
11. Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012;60(14):1231-8
12. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166(3):597-603
13. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008;5(4):319-35
14. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32(11): 1345-61
15. Obarzanek E, Sacks FM, Vollmer WM, et al. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 2001;74(1): 80-9
16. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369(2):145-54
17. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012;308(23): 2489-96
18. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170(17): 1566-75
19. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368(14):1279-90
20. Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 2011;124(9):841-51.e842
21. Gylling H, Hallikainen M, Nissinen MJ, et al. Very high plant stanol intake and serum plant stanols and non-cholesterol sterols. Eur J Nutr 2010;49(2):111-17
22. Mensink RP, de Jong A, Lütjohann D, et al. Plant stanols dose-dependently decrease LDL-cholesterol concentrations, but not cholesterol-standardized fat-soluble antioxidant concentrations, at intakes up to 9 g/d. Am J Clin Nutr 2010;92(1):24-33
23. Brinton EA. Effects of ethanol intake on lipoproteins. Curr Atheroscler Rep 2012; 14(2):108-14
24. Bessembinders K, Wielders J, van de Wiel A. Severe hypertriglyceridemia influenced by alcohol (SHIBA). Alcohol Alcohol 2011;46(2):113-16
25. Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009;150(12):830-9
26. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105(2): 198-204
27. Verhoeven V, Lopez Hartmann M, Remmen R, et al. Red yeast rice lowers cholesterol in physicians-a double blind, placebo controlled randomized trial. BMC Complement Altern Med 2013;13(1):178
28. Na LX, Li Y, Pan HZ, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res 2012;57:1569-77
29. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, et al. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem 2013;25: 144-50
30. Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs 2010;10(5):305-14
31. Goldberg RB, Rosenson RS, Hernandez-Triana E, et al. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol 2012;6(4):318-24
32. Goldberg RB, Rosenson RS, Hernandez-Triana E, et al. Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diab Vasc Dis Res 2013; 10(3):256-62
33. Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol 2011;108(8): 1129-35
34. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168(18):1975-83
35. Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012;55(2): 432-42
36. Romanelli RJ, Leahy A, Jukes T, et al. Colesevelam in the treatment of hypercholesterolemia and hyperglycemia: a retrospective analysis from an ambulatory care medical network. Curr Med Res Opin 2013;29(12):1747-56
37. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2, 722 people: systematic review and meta analysis of randomized controlled trials. J Intern Med 2009;265(5):568-80
38. Carabello BA. The SEAS Trial. Curr Cardiol Rep 2010;12(2):122-4
39. Bang CN, Greve AM, Boman K, et al. Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am Heart J 2012;163(4):690-6
40. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784):2181-92
41. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156(5):826-32
42. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010;159(5):705-9
43. Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007;13(1):11-16
44. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010;33(5): 1134-9
45. Tamaki N, Ueno H, Morinaga Y, et al. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2012;19(6):532-8
46. Han SH, Oh PC, Lim S, et al. Comparative cardiometabolic effects of fibrates and omega-3 fatty acids. Int J Cardiol 2013;167:2404-11
47. Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 2013;19(17):3124-31
48. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500):1849-61
49. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17): 1563-74
50. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009;32(3):493-8
51. Tonkin AM, Chen L. Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Circulation 2010;122(8): 850-2
52. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370(9600):1687-97
53. Davis TME, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54(2):280-90
54. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376(9739):419-30
55. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375(9729):1875-84
56. Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011;217(2): 492-8
57. McKenney JM, Farnier M, Lo K-W, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47(8):1584-7
58. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010; 126(3):314-45
59. Malik S, Kashyap ML. Niacin, lipids, and heart disease. Curr Cardiol Rep 2003;5(6): 470-6
60. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8(6): 1245-55
61. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345(22):1583-92
62. Taylor AJ. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110(23):3512-17
63. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3*. Curr Med Res Opin 2006;22(11):2243-50
64. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
65. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17): 1279-91
66. Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides and impact on global health outcomes (AIM-HIGH) trial. J Am Coll Cardiol 2013;62(17):1580-4
67. Gotto AM Jr, Moon JE. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study. Expert Rev Cardiovasc Ther 2012; 10(8):955-63
68. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356(13):1304-16
69. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357(21):2109-22
70. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154(7):1465-73
71. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367(22):2089-99
72. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363(25):2406-15
73. Nicholls SJ, Brewer H, Kastelein JP, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306(19):2099-109
74. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010; 376(9740):540-50
75. The ORIGIN Trial Investigators. n-Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. N Engl J Med 2012;367:309-18
76. The Risk and Prevention Study Collaborative Group. n-fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368(19):1800-8
77. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events-a systematic review and meta-analysis. JAMA 2012; 308(10):1024-33
78. Kwak SM, Myung SK, Lee YJ, Seo HG; Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172(9):686-94
79. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr 2012;107:S201-13
80. Zheng T, Zhao J, Wang Y, et al. The limited effect of omega-3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: a meta-analysis. Clin Biochem 2013. [Epub ahead of print]
81. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112(4):298-304
82. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009;32(7):365-72
83. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Br Med J 2010;341:c6273
84. Kromhout D, Giltay EJ, Geleijnse JM. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363(21):2015-26
85. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction clinical perspective. Circulation 2010;122(21):2152-9
86. Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2010;17(5): 588-92
87. DiNicolantonio JJ, O'Keefe JH, Lavie CJ. The big ones that got away: omega-3 meta-analysis flawed by excluding the biggest fish oil trials. Arch Intern Med 2012;172(18): 1427-8
88. Avanzini F, Barlera S, Caimi V, et al. Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials 2010;11:68
89. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and. OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33(1):159-71
90. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090-8
91. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108(5):682-90
92. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study). Am J Cardiol 2012;110(7):984-92
93. Sarbolouki S, Javanbakht MH, Derakhshanian H, et al. Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial. Singapore Med J 2013;54(7):387-90
94. Tani S, Nagao K, Matsumoto M, et al. Highly purified eicosapentaenoic acid may increase the low-density lipoprotein particle size by improving triglyceride metabolism in patients with hypertriglyceridemia. Eur Heart J 2013;34(Suppl 1):P695
95. Demonty I, Chan Y-M, Pelled D, Jones PJ. Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols. Am J clin Nutr 2006;84(6): 1534-42
96. Bitzur R, Cohen H, Cohen T, et al. The metabolic effects of omega-3 plant sterol esters in mixed hyperlipidemic subjects. Cardiovasc Drugs Ther 2010;24(5-6): 429-37
97. Meier JJ, Gethmann A, Götze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006;49(3):452-8
98. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13(4):302-12
99. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29(1):14-25
100. Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15(2):112-20
101. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
102. Sprecher DL, Massien C, Pearce G, et al. Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor d agonist. Arterioscler Thromb Vasc Biol 2007;27(2):359-65
103. Risérus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR) d promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57(2):332-9
104. Ehrenborg E, Skogsberg J. Peroxisome proliferator-activated receptor delta and cardiovascular disease. Atherosclerosis 2013; 231(1):95-106
105. Bays HE, Schwartz S, Littlejohn T, et al. MBX-8025, a novel peroxisome proliferator receptor-d agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 2011; 96(9):2889-97
106. Choi Y-J, Roberts BK, Wang X, et al. Effects of the PPAR-d agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 2012;220(2):470-6
107. Cariou B, Zäir Y, Staels B, Bruckert E. Effects of the new dual PPARa/d agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34(9): 2008-14
108. Lincoff AM, Tardif J-C, Neal B, et al. Evaluation of the dual peroxisome proliferator-activated receptor a/g agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J 2013;166(3):429-34.e421
109. Fruchart J-C. Selective peroxisome proliferator-activated receptoralpha modulators (SPPARMalpha): the next generation of peroxisome proliferator- activated receptor alpha-agonists. Cardiovasc Diabetol 2013;12(1):82
110. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 2008;18(1):6-14
111. Yoshida K, Shimizugawa T, Ono M, Furukawa H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res 2002;43(11):1770-2
112. Lee EC, Desai U, Gololobov G, et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem 2009;284(20): 13735-45
113. Nakajima K, Kobayashi J. Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178. Expert Opin Ther Pat 2014;24(1):113-19
114. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res 2011;52(2): 189-206
115. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012;272(2):185-96
116. Seda G, Meyer JM, Amundson DE, Daheshia M. Plasmapheresis in the management of severe hypertriglyceridemia. Crit Care Nurse 2013;33(4):18-23
117. Hovland A, Hardersen R, Mollnes TE, Lappega°rd KT. Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. JOP 2010;11(5):467-9
118. Bayraktaroglu T, Ozkaya M, Kutluturk F, et al. Severe hypertriglyceridemia and triglyceride apheresis. Endocr Abstracts 2009;20:P437
119. Chen J-H, Yeh J-H, Lai H-W, Liao C-S. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol 2004;10(15):2272-4
120. Ewald PDDN, Kloer H-U. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl 2012;7(1):31-5
121. Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013;20(4):361-9
122. Wierzbicki AS, Viljoen A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin Biol Ther 2013;13(1):7-10
123. Carpentier AC, Frisch F, Labbé SM, et al. Effect of Alipogene Tiparvovec (AAV1-LPLS447X) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients. J Clin Endocrinol Metab 2012; 97(5):1635-44
124. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM 1997;90(10): 631-4
125. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358(14):1431-43
126. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010;32(4): 615-25
127. Kawashiri M-A, Nohara A, Noguchi T, et al. Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia. Am J Cardiol 2012;109(3):364-9
128. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50(Suppl): S172-7
129. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380(9836):29-36
130. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367(20):1891-900
131. Dias C, Shaywitz A, Cooke B, et al. Effects of AMG 145, a fully human monoclonal antibody against PCSK9, on low-density lipoprotein cholesterol in subjects taking statins: a phase 1, randomized, double-blind, placebo-controlled, ascending multiple-dose study. J Am Coll Cardiol 2012;59(13s1):E1379-9
132. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007-17
133. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012;380: 1995-2006
134. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemiaclinical perspective the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012;126(20):2408-17
135. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS Randomized Trial AMG145 in statin-intolerant patients. JAMA 2012;308(23):2497-506
136. Blom DJ, Marais AD, Raal FJ, Lambert G. The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. Clin Lipidol 2013;8(2): 243-56
137. Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1a and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010;51(6):1486-95
138. Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010;51(9): 2714-21
139. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004;24(8):1454-9
140. Kastelein JJP, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114(16):1729-35
141. Akdim F, Stroes ESG, Sijbrands EJG, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010;55(15):1611-18
142. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010;51(5):1057-62
143. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105(10):1413-19
144. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375(9719):998-1006
145. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012; 33(9):1142-9
146. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011;32(21): 2650-9
147. Goldberg AC. Emerging LDL therapies: microsomal triglyceride transfer protein inhibitors. J Clin Lipidol 2013;7(3): S16-20
148. Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 2012;7:29-38
149. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356(2):148-56
150. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381(9860):40-6
151. Tuteja S, Duffy D, Dunbar RL, et al. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy 2013. [Epub ahead of print]
152. Nenseter MS, Bogsrud MP, Græsdal A, et al. LDL-apheresis affects markers of endothelial function in patients with homozygous familial hypercholesterolemia. Thromb Res 2012;130(5):823-5
153. Græsdal A, Bogsrud MP, Holven KB, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012;6(4):331-9
154. Castilla Cabezas JA, López-Cillero P, Jiménez J, et al. Role of orthotopic liver transplant in the treatment of homozygous familial hypercholesterolemia. Rev Esp Enferm Dig 2000;92(9):601-8
155. Lopez-Santamaria M, Migliazza L, Gamez M, et al. Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass. J Pediatr Surg 2000;35(4):630-3
156. Kakaei F, Nikeghbalian S, Kazemi K, et al. Liver transplantation for homozygous familial hypercholesterolemia: two case reports. Transplant Proc 2009;41(7): 2939-41
157. Maiorana A, Nobili V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant 2011;15(2):E25-9
158. Raper A, Kolansky DM, Cuchel M. Treatment of familial hypercholesterolemia: is there a need beyond statin therapy? Curr Atheroscler Rep 2012;14(1):11-16
159. Hovingh GK, Davidson MH, Kastelein JJP, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013;34(13):962-71
160. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med 2009;361(26):2518-28
161. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BRG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. J Am Med Assoc 2009;301(22):2331-9
162. Eaton DL, Fless GM, Kohr WJ, et al. Partial amino acid sequence of apolipoprotein (a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987;84(10):3224-8
163. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein (a) atherogenicity. Curr Opin Lipidol 2008;19(4):369-77
164. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353(1):46-57
165. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009; 119(13):1711-19
166. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Investig 1992;90(1):52-60
167. Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein (a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 2010; 3(1):39-46
168. Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2013. [Epub ahead of print]
169. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31(23):2844-53
170. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011;5(5):338-67
171. Van Wissen S, Smilde TJ, Trip MD, et al. Long term statin treatment reduces lipoprotein (a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003;89(8):893-6
172. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial. Circulation 2013. [Epub ahead of print]
173. Carlson LA, Hamsten A, Asplund A, Pronounced lowering of serum levels of lipoprotein Lp (a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226(4):271-6
174. Chennamsetty I, Kostner KM, Claudel T, et al. Nicotinic acid inhibits hepatic APOA gene expression: Studies in humans and in transgenic mice. J Lipid Res 2012; 53(11):2405-12
175. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013; 62(17):1575-9
176. Cenarro A, Puzo J, Ferrando J, et al. Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. Metabolism 2013. [Epub ahead of print]
177. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein (a) in patients with atherosclerotic diseases. Clin Chem 2002;48(9):1454-9
178. Ranga GS, Kalra OP, Tandon H, et al. Effect of aspirin on lipoprotein (a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2007;16(5):220-4
179. Kagawa A, Azuma H, Akaike M, et al. Aspirin reduces apolipoprotein (a)(apo (a)) production in human hepatocytes by suppression of apo (a) gene transcription. J Biol Chem 1999;274(48):34111-15
180. Ariyo A, Hennekens CH, Stampfer MJ, Ridker PM. Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study. J Cardiovasc Risk 1998;5(4):273-8
181. Desai NR, Kohli P, Giugliano RP, et al. AMG 145, a monoclonal antibody against PCSK9, significantly reduces lipoprotein (a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LAPLACE-TIMI 57 Trial. Circulation 2013. [Epub ahead of print]
182. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6(3): 229-39
183. Ibrahim M, Ussen B, Pottle A, Barbir M. Low-density lipoprotein apheresis is effective in reducing lipoprotein (a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery disease. J Clin Lipidol 2012; 6(2):192-4
184. Leebmann J, Roseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease: prospective Observational Multicenter Study. Circulation 2013;128(24):2567-76
185. Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013;14(1): 93-9
186. Derosa G, Cicero AFG, Gaddi A, et al. The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25(5):1429-39
187. Sirtori CR, Calabresi L, Ferrara S, et al. L-carnitine reduces plasma lipoprotein (a) levels in patients with hyper Lp (a). Nutr Metab Cardiovasc Dis 2000;10(5): 247-51
188. Shakeri A, Tabibi H, Hedayati M. Effects of l-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int 2010; 14(4):498-504
189. Schlueter W, Keilani T, Batlle DC. Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein (a) by fosinopril. Am J Cardiol 1993;72(20):H37-44
190. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996;122(1):89-95
191. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996; 77(14):1244-7
192. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 1994;14(10):1586-93
193. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. Circulation 1998;97(10):979-86
194. Müller H, Lindman AS, Blomfeldt A, et al. A diet rich in coconut oil reduces diurnal postprandial variations in circulating tissue plasminogen activator antigen and fasting lipoprotein (a) compared with a diet rich in unsaturated fat in women. J Nutr 2003; 133(11):3422-7
195. Yildirimkaya M, Ozata M, Yilmaz K, et al. Lipoprotein (a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy. Endocr J 1996; 43(6):731-6
196. Milionis HJ, Efstathiadou Z, Tselepis AD, et al. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid 2003;13(4):365-9
197. Kung AW, Pang RW, Lauder I, et al. Changes in serum lipoprotein (a) and lipids during treatment of hyperthyroidism. Clin Chem 1995;41(2):226-31
198. Triguero MLM, Hernández-Mijares A, Nguyen TT, et al. Effect of thyroid hormone replacement on lipoprotein (a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc 1998;73: 837-41
199. Besseling J, van Capelleveen J, Kastelein JJ, Hovingh GK. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there? Drugs 2013;73: 293-301
200. Thompson GR, Seed M. Lipoprotein (a): the underestimated cardiovascular risk factor. Heart 2013. [Epub ahead of print]
201. Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Investig 2011;121(9):3724-34
202. Morishita R, Yamada S, Yamamoto K, et al. Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. Circulation 1998;98(18): 1898-904
203. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011;57(15):1611-21
204. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009;30(11):570-80
205. Evans MJ, Mahaney PE, Borges-Marcucci L, et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 2009;296(3): G543-52
206. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145(3): 574-82.e571